Brief Blog: Diaceutics releases a 25-page white paper on improving precision medicine access in lung cancer (NSCLC).
Find it here:
"Addressing the Economic and Operational Issues of the Clinical Practice Gaps in NSCLC."
https://lp.diaceutics.com/econpaper/
##
According to Diaceutics, "This paper outlines the 5 critical recommendations developed by The Health and Economic Forum to provide industry and policy makers with valuable and clear economic guidance and recommendations to overcome the challenges obstructing the advancement of precision medicine."
It's open access at the above link (email registration). See subscription coverage at Genomeweb here.
##
Separately, see Diaceutics Highlights from ESMO - here.
See also a new paper, August 2024, from Hofman, Liquid and Tissue Biopsies in Lung Cancer: Algorithms and Perspectives, open access at Cancers, here. He writes that appropriate genomics and biopsies (or LBx) are not well-integrated and this could be improved by standard practices and algorithms.
###
AI CORNER
Here's a mini summary by AI of Hofman:
- Liquid biopsies, especially for non-small cell lung cancer (NSCLC), offer a valuable complement to tissue biopsies by detecting actionable mutations through circulating tumor DNA (ct-DNA) analysis. Next-generation sequencing (NGS) enhances this, enabling complex genomic profiling for targeted therapies.
- While tissue biopsies remain the gold standard, liquid biopsies are faster, less invasive, and crucial when tissue samples are insufficient. However, cost and infrastructure issues, particularly in Europe, limit routine use.
- The author concludes that standardized practices and algorithms would improve the availability of genomic information, benefiting both clinicians and patients
